Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Please use the sharing tools found via the share button at the top or side of articles. Copying articles to share with others is a breach of FT.com T&Cs and Copyright Policy. Email licensing@ft.com to buy additional rights. Subscribers may share up to 10 or 20 articles per month using the gift article service. More information can be found at https://www.ft.com/tour.
https://www.ft.com/content/0edad695-bd3b-40cb-8584-55815a4c98c1
( interesting statement ring a bell ? )
He said the deal’s real value lies in the pipeline of drugs earlier in development, which are trying to improve on the market leaders by making them more lethal to cancer cells but safer to administer.
https://www.ft.com/content/0edad695-bd3b-40cb-8584-55815a4c98c1
What is Affyxell about to be Valued at ?
AFX-001
AFX-002
http://affyxell.com/pipeline/pipeline.php
https://avacta.com/therapeutics/pipeline/
Header Say's it all ..... interesting to see amount spent on Affimer .... Research costs relating to new diagnostic tests in the Diagnostics Division wonder what we got coming test wise ?
N the financial year to 31 December 2021, Launch Diagnostics generated revenues related to sales of products for COVID-19 testing and products unrelated to COVID-19. Launch Diagnostics’ core, non-COVID-19 revenues were £14.17 million and total revenues were £32.75 million with total Adjusted EBITDA of £8.52 million[3] and a profit before tax of £9.36 million. As of 31 December 2021, Launch Diagnostics had net assets of £17.0 million. Launch Diagnostics’ FY21 revenues were geographically split between the UK and France and the Benelux region, with the former accounting for £23.85 million and the latter £8.9 million.
During FY20 and FY21, Launch Diagnostics’ revenue growth was driven primarily by its COVID-19 testing products and, whilst these revenues have been discounted by 80% in Avacta’s valuation of the business, the Company believes there is still potential for some sustainable ongoing COVID test revenues from symptomatic testing in hospitals. During the past two years, the focus on COVID-19 testing saw Launch Diagnostics’ sales of non-COVID-19 products fall from £18.51 million in FY19 to £14.17 million in FY21, but this business is now increasing as customers return to normal purchasing cycles.
Haven't seen this before apologies if already posted ?
https://www.withpower.com/trial/phase-1-sarcoma-6-2021-6f477
7 Day's till Investor Presentation as per previous years we will get plenty of Updates ......... My money is on a licensing deal prior to results IMHO if so these Golden Tickets will be sold out ..... ( Avacta Getting On With It ! )